(Q37931985)

25 August 2017

1 reference

title

Current options for the management of postmenopausal osteoporosis (English)

1 reference

25 August 2017

0 references

2

Jean-Yves Reginster

1 reference

25 August 2017

Marie-Paule Lecart

1

1 reference

PubMed ID

21916810

25 August 2017

language of work or name

English

0 references

publication date

15 September 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

16

1 reference

25 August 2017

2533-2552

1 reference

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Risk of new vertebral fracture in the year following a fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

A meta-analysis of previous fracture and subsequent fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Hip fractures in the elderly: a world-wide projection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Management of osteoporosis in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Mortality risk after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Excess mortality following hip fracture: a systematic epidemiological review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Quality of life related to fear of falling and hip fracture in older women: a time trade off study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Osteoporosis: a still increasing prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Vitamin D3 and calcium to prevent hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Annual injection of vitamin D and fractures of aged bones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Anti-vertebral fracture efficacy of raloxifene: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Safety of bisphosphonates in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Bisphosphonates and atrial fibrillation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Bisphosphonate associated osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Low-energy femoral shaft fractures associated with alendronate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Low incidence of anti-osteoporosis treatment after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Strontium ranelate in the prevention of osteoporotic fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

S 12911-2 inhibits osteoclastic bone resorption in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Strontium ranelate may cause alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Risk of Mortality Following Clinical Fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.618123

10.1517/14656566.2011.618123

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21916810